Nuvation Bio's IBTROZI (taletrectinib) demonstrated a median duration of response of nearly 50 months and progression-free survival of 46.1 months in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer. The drug showed high overall response rates (89.8%) and strong intracranial activity, with response rates of 76.5% in patients with brain metastases. Safety data indicated a manageable profile with low neurological side effects and no new safety concerns. These results, presented at AACR 2026 and published in the Journal of Clinical Oncology, reinforce IBTROZI's potential as a durable and effective treatment option, with ongoing studies aiming to expand its use globally.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
